Results 181 to 190 of about 184,218 (302)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

PTSD recovery, spatial processing, and the val66met polymorphism. [PDF]

, 2014
Miller, J.K., Wiener, J.M.
core   +2 more sources

Fibronectin type III domain-containing protein 5/irisin in extracellular vesicles is reduced in older individuals. [PDF]

Brain Commun
Hunter TR, Lyra E Silva NM, de Freitas GB, Rody T, Santos LE, Zhang J, Bullock A, Tartaglia MC, Abraham S, Nicolini C, Nelson AJ, Heisz JJ, Fahnestock M, De Felice FG.   +13 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Quetiapine ameliorates sensorimotor gating, recognition memory, and neuroendocrine plasticity in chronic stress-induced female rats. [PDF]

Metab Brain Dis
Çevreli B, Özcan ÖÖ, Kayıkçı K, Başıeğri Eİ.   +3 more
europepmc   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Serum BDNF levels as a potential prognostic marker for functional recovery in stroke: Preliminary findings from a prospective observational study. [PDF]

PLoS One
Shin S, Kim H, Kim DH, Chang WH.
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Establishing an RNA Sensor with High Sensitivity and Dynamic Range Utilizing a Signal Amplifier Platform. [PDF]

ACS Synth Biol
Lim HE, Llanos CD, Chappell J, Segatori L.   +3 more
europepmc   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source